TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03327753

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor control exercises
Description: The first stage of the treatment involves assessment of symptoms and implementation of a retraining program designed to improve activity of muscles assessed to have poor control and reducing activity of any muscle identified to be overactive. Participants are taught how to contract these muscles independently from the superficial trunk muscles and progress until the patient are able to maintain isolated contractions of the target muscles. During this stage exercises for breathing control, posture of spine and lower limb and movement are performed. The second stage of the treatment involved the progression of the exercises towards more functional activities. Throughout this process the recruitment of the trunk muscles, posture, movement pattern and breathing are assessed and corrected.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Graded activity
Description: The program is based on activities that each patient identify as problematic and that they cannot perform or have difficulty performing because of their back pain. The activities in the program are progressed in a time-contingent manner from the baseline assessed ability to a target goal set jointly by patient and therapist. Patients receive daily quotas and are instructed to only perform the agreed amount, even when they feel they are capable of doing more. Cognitive-behavioural principles are used to help patients overcome the natural anxiety associated with pain and activities. Physiotherapists use positive reinforcement, explain pain mechanisms and addressed negative behaviours and pain-related anxiety. A plan for managing relapses is developed between therapists and patients.
Study: NCT02408796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTO-201
Study: NCT03820037

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ongentys
Description: single oral 50 mg (capsule containing 50 mg OPC) under fasting conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067 (test)
Description: single oral 50 mg (capsule containing 50 mg OPC) under fasting conditions
Study: NCT01912729

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Networked Peer Support with Peer Guide
Description: Participants will have access to tools and lessons based on Cognitive Behavior Therapy through a web application that can be accessed on a smartphone or computer. Additionally, participants will have access to a private social network that connects them with other participants in the study. Participants will be supported by a peer guide. The peer guide will be another high school student around the same age as participants.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Networked Peer Support with Clinician Coach
Description: Participants will have access to tools and lessons based on Cognitive Behavior Therapy through a web application that can be accessed on a smartphone or computer. Additionally, participants will have access to a private social network that connects them with other participants in the study. Participants will be supported by a clinical psychologist.
Study: NCT04597034

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AN69-Oxiris
Description: To demonstrate clinical efficacy of AN69-Oxiris membrane to reach a stable MAP, with less vasopressor dosing (at least 0.1 micrograms/kg/min) after 72h of treatment, compared to a conventional membrane (standard AN69) in critically ill patients with AKI, COVID-19 infection and requirement of continuous renal replacement therapy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AN69-Standard
Description: Standard treatment.
Study: NCT02154126

Intervention type: DEVICE
Group type: OTHER
Intervention: Continuous Glucose Monitoring Device (Senseonics)
Study: NCT01986634

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laser Treatment
Description: Patient will have split face laser resurfacing as per standard of care. One side of the face will be treated with a standardized single depth laser peel. The other side of the perioral area will be treated with variant, deeper treatment to perioral rhytids.
Study: NCT00057837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Arm PET: 70 mg/m2 IV over 60 minutes on days 8, 9 and 10 of each cycle. Arm PIE: 85 mg/m2 orally (divided into 2 doses, 12 hours apart) on day 3 and 10 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Arm PET: 70 mg/m2 IV over 60 minutes on days 8, 9 and 10 of each cycle. Arm PIE: 85 mg/m2 orally (divided into 2 doses, 12 hours apart) on day 3 and 10 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 50 mg/m2 IV over 90 minutes on days 1 and 8 of each cycle (Arm PIE only).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Topotecan 0.75 mg/m2 IV over 30 minutes on days 1,2 and 3 of each cycle (Arm PET only).
Study: NCT04419285

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Locomotion task
Description: The locomotion task takes place on a Streetlab platform. The subject must follow a line on the ground, straight or composed of turns.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Posturology task SOT (Sensory Organization Test)
Description: The task takes place on a Streetlab platform with uniform walls without decorations in order to remove any localization element.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The quality of life questionnaire
Description: Study the correlations between the subjects' quality of life scores and the results during behavioral tests. Identify the subjective parameters most sensitive to sensory-motor performance.
Study: NCT01107756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LENOGRASTIM (GRANOGYTE 34)
Description: Pharmaceutical form: solution Route of administration: intravenous Dose regimen:recommended dosing as per Granocyte 34 package insert
Study: NCT00712322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darifenacin
Description: Following a 7-day washout period, participants received darifenacin liquid oral suspension up to 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darifenacin
Description: Following a 7-day washout period, participants received darifenacin liquid oral suspension up to 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darifenacin
Description: Following a 7-day washout period, participants received darifenacin liquid oral suspension up to 14 days.
Study: NCT03608553

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR Guided Focused Ultrasound
Description: Blood Brain Barrier Disruption using FUS
Study: NCT02375633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW-330SR2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pelubiprofen
Study: NCT01755494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg
Description: Saxagliptin oral tablet 5mg, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg
Description: Saxagliptin oral tablet 5mg, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin XR 500 mg
Description: Metformin XR oral tablet 500 mg, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mertformin XR 2 x 500 mg
Description: Metformin XR oral tablet 2 x 500 mg, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Komboglyze XR 5/500 mg
Description: oral FDC tablet (saxagliptin 5 mg and metformin 500 mg), single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Komboglyze XR 5/1000 mg
Description: oral FDC tablet (saxagliptin 5 mg and metformin 1000 mg), single dose
Study: NCT04651725

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercises
Description: Patients were planned to complete exercise sessions 3 times a week for 12 weeks, each lasting 35 minutes per day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercises
Description: Patients were planned to complete exercise sessions 3 times a week for 12 weeks, each lasting 35 minutes per day.
Study: NCT03005886

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GCF sampling
Description: GCF samples were collected using commercially available periopaper . The sample site was gently air-dried and all supragingival plaque was removed. The area was carefully isolated with cotton rolls and a saliva ejector was used to prevent the samples from being contaminated by saliva. The paper strips were inserted into the pockets until slight resistance was felt and left in place for 30s.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: GCF sampling
Description: GCF samples were collected using commercially available periopaper . The sample site was gently air-dried and all supragingival plaque was removed. The area was carefully isolated with cotton rolls and a saliva ejector was used to prevent the samples from being contaminated by saliva. The paper strips were inserted into the pockets until slight resistance was felt and left in place for 30s.
Study: NCT05033509

Intervention type: OTHER
Intervention: supervision the Kidney fonction on ECMO
Description: patients who benefited from ECMO, and presented an acute kidney injury afterwards
Study: NCT02260245

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Team training using the TeamSTEPPS model
Description: Two or three master trainers from each affiliate will be undergo train-the-trainer training to bring back to their affiliate.
Study: NCT02511951

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pancreaticojejunostomy
Description: To create the posterior suturing layers, the needle is inserted from the posterior interior side of the pancreatic duct, passing through the dorsal region of the parenchyma of the pancreatic stump to the posterior surface of the pancreas approximately 0.5 cm distal to the cut edge. The other side of the needle starts from the inside of the jejunum lumen to the subserosa and then passes through the seromuscular layer to the posterior surface of the bowel.The anterior suturing layer is performed in the same manner.~Two layer anatomosis with Duct-to-Mucosa pancreaticojejunostomy is performed by suturing the pancreatic parenchyma to the jejunal seromuscular layer and no stenting tube was used.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pancreaticojejunostomy
Description: To create the posterior suturing layers, the needle is inserted from the posterior interior side of the pancreatic duct, passing through the dorsal region of the parenchyma of the pancreatic stump to the posterior surface of the pancreas approximately 0.5 cm distal to the cut edge. The other side of the needle starts from the inside of the jejunum lumen to the subserosa and then passes through the seromuscular layer to the posterior surface of the bowel.The anterior suturing layer is performed in the same manner.~Two layer anatomosis with Duct-to-Mucosa pancreaticojejunostomy is performed by suturing the pancreatic parenchyma to the jejunal seromuscular layer and no stenting tube was used.
Study: NCT02450526

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50 Units
Study: NCT03059810

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A
Description: Investigational Contact Lens
Study: NCT01228266

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous mesenchymal stem cells
Description: A randomized double-blind, crossover study comparing treatment with autologous MSC vs. suspension media on patients with active MS
Study: NCT02696915

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients received ultrasound guided fascial iliaca compartment blockade using normal saline 0.9%, 40 ml
Study: NCT02450526

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 20 Units
Study: NCT03902002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omaveloxolone 50 mg capsules
Description: Capsules containing 50 mg of omaveloxolone
Study: NCT02696915

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Patients received ultrasound guided fascial iliaca compartment blockade using bupivacaine 0.25%, 40 ml

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided fascia iliaca compartment block
Description: Ultrasound guided fascia iliaca compartment block
Study: NCT02696915

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Ultrasound guided fascia iliaca compartment block
Description: Ultrasound guided fascia iliaca compartment block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal medications (bupivacaine (15 mg) in conjunction with fentanyl 20 micrograms)
Description: Intrathecal hyperbaric bupivacaine (15 mg) in conjunction with fentanyl 20 micrograms

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intrathecal medications (bupivacaine (15 mg) in conjunction with fentanyl 20 micrograms)
Description: Intrathecal hyperbaric bupivacaine (15 mg) in conjunction with fentanyl 20 micrograms
Study: NCT01127126

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bryophyllum pinnatum, Placebo in form of Lactose
Description: Comparison Bryophyllum (2100mg/d) against Placebo (2100mg/d) regarding effectivity and safety.~Bryophyllum and Placebo are both administered for 8 weeks. Bryophyllum and Placebo are both given in form of capsules, 350mg per capsule, 2-2-2/d.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bryophyllum pinnatum, Placebo in form of Lactose
Description: Comparison Bryophyllum (2100mg/d) against Placebo (2100mg/d) regarding effectivity and safety.~Bryophyllum and Placebo are both administered for 8 weeks. Bryophyllum and Placebo are both given in form of capsules, 350mg per capsule, 2-2-2/d.
Study: NCT02896907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV
Study: NCT03902002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omaveloxolone 50 mg capsules
Description: Capsules containing 50 mg of omaveloxolone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omaveloxolone 50 mg capsules
Description: Capsules containing 50 mg of omaveloxolone
Study: NCT03005886

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: GCF sampling
Description: GCF samples were collected using commercially available periopaper . The sample site was gently air-dried and all supragingival plaque was removed. The area was carefully isolated with cotton rolls and a saliva ejector was used to prevent the samples from being contaminated by saliva. The paper strips were inserted into the pockets until slight resistance was felt and left in place for 30s.
Study: NCT01373879

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh63 ME-TRAP, MVA ME-TRAP
Description: AdCh63 ME-TRAP 1 x 10\^10vp IM followed by MVA ME-TRAP 2 x 10\^8 pfu IM 8 weeks later

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh63 ME-TRAP, MVA ME-TRAP
Description: AdCh63 ME-TRAP 5 x 10\^10vp IM followed by MVA ME-TRAP 2 x 10\^8 pfu IM 8 weeks later

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh63 ME-TRAP, MVA ME-TRAP
Description: AdCh63 ME-TRAP 1 x 10\^10vp IM followed by MVA ME-TRAP 1 x 10\^8 pfu IM 8 weeks later

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh63 ME-TRAP, MVA ME-TRAP
Description: AdCh63 ME-TRAP 1 x 10\^10vp IM followed by MVA ME-TRAP 2 x 10\^8 pfu IM 8 weeks later

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HDCRV
Description: HDCRV 1ml IM followed by HDCRV 1ml IM 8 weeks later

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh63 ME-TRAP, MVA ME-TRAP
Description: AdCh63 ME-TRAP 5 x 10\^10vp IM followed by MVA ME-TRAP 1 x 10\^8 pfu IM 8 weeks later

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh63 ME-TRAP, MVA ME-TRAP
Description: AdCh63 ME-TRAP 5 x 10\^10vp IM followed by MVA ME-TRAP 2 x 10\^8 pfu IM 8 weeks later

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HDCRV
Description: HDCRV 1ml IM followed by HDCRV 1ml IM 8 weeks later
Study: NCT01286558

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 40 mg telmisartan
Description: once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 mg amlodipine
Description: once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5 mg amlodipine
Description: once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 80 mg telmisartan
Description: once daily
Study: NCT03534193

Intervention type: OTHER
Group type: OTHER
Intervention: Molly Center Diabetes Care Guide (Paper-based)
Description: Diabetes education with Registered Nurse in addition to Paper based education modules

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Molly Center Diabetes Care Guide (Paper-based)
Description: Diabetes education with Registered Nurse in addition to Paper based education modules

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tablet based interactive diabetes education modules
Description: Molly Center Standard Diabetes Education plus access to interactive diabetes education modules through bedside tablet.
Study: NCT04917081

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Self-Compassion
Description: Mindful Self-Compassion has been developed by Neff and Germer as a specific kind of Mindfulness-Based Interventions to promote self-compassion. It combines the skills of mindfulness and self-compassion, providing a powerful tool for emotional resilience and enhancing the capacity for emotional wellbeing. In this study, a shortened version of the MSC program is used which is applied once a week for 75 minutes throughout the patients' stay in the rehabilitation clinic.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Muscle Relaxation
Description: Progressive Muscle Relaxation by Jacobson is a deep relaxation technique that helps relieve muscle tension and is based on the premise that mental calmness is a natural result of physical relaxation. In this study, Progressive Muscle Relaxation is applied once a week for 75 minutes throughout the patients' stay in the rehabilitation clinic.
Study: NCT02619448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: chemotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 70 Gy in 20 fractions over 4 weeks
Description: accelerated hypofractionated RT
Study: NCT03005886

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: phase I therapy
Description: comprehensive proper plaque control program, scaling, subgingival curettage and root Phase I Periodontal Therapy planning

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: phase I therapy
Description: comprehensive proper plaque control program, scaling, subgingival curettage and root Phase I Periodontal Therapy planning
Study: NCT01737892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm T Epinephrine Inhalation Aerosol HFA, 125 mcg, 1 inhalation
Description: Epinephrine Inhalation Aerosol HFA, Single dose 125 mcg, 1 inhalation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm C-Epinephrine Inhalation Aerosol CFC
Description: Epinephrine Inhalation Aerosol - CFC, Single dose 220 mcg, 1 inhalation
Study: NCT02530255

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cycloastragenol
Description: Oral telomerase activator - cycloastragenol.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo (for cycloastragenol)
Description: placebo comparator, placebo for cycloastragenol.
Study: NCT01348893

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: 12 to 16 weeks of group yoga classes (approximately 32 classes per student), 30-45 minutes per class, 2-3 times per week, during physical education class. Yoga program includes physical postures and movement, breathing exercises, partner/group games, deep relaxation and meditative techniques.
Study: NCT01729039

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: standard balance rehabilitation
Description: All subjects perform balance and gait exercises in addition to eye exercises and receive a written home exercise program (HEP) of balance and gait exercises to improve postural stability and mobility with progressively challenging tasks. Balance exercises include maintaining stability with vision and somatosensory cues altered, dynamic weight shifts and performing ankle, hip and step strategies. Gait activities include negotiating uneven terrains and obstacles, gait with head turns, varied speed, and unpredictable starts and stops. Walking for endurance is included in the HEP. Each participant receives a customized balance and gait HEP based on identified impairments and is progressed according to ability and level of assistance at home.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: standard balance rehabilitation
Description: All subjects perform balance and gait exercises in addition to eye exercises and receive a written home exercise program (HEP) of balance and gait exercises to improve postural stability and mobility with progressively challenging tasks. Balance exercises include maintaining stability with vision and somatosensory cues altered, dynamic weight shifts and performing ankle, hip and step strategies. Gait activities include negotiating uneven terrains and obstacles, gait with head turns, varied speed, and unpredictable starts and stops. Walking for endurance is included in the HEP. Each participant receives a customized balance and gait HEP based on identified impairments and is progressed according to ability and level of assistance at home.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: gaze stability
Description: Vestibular adaptation and substitution exercises will be performed by the experimental group (GS). Adaptation exercises involve head movement while maintaining focus on a target, which may be stationary or moving. Typical progression of adaptation exercises involve increased velocity of head movement, movement of both target and head, target placed in a distracting visual pattern and maintenance of a challenging posture. During active eye-head exercise, a large eye movement to a target is made prior to the head moving to face the target, potentially facilitating use of preprogrammed eye movements.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The placebo exercises will consist of saccadic eye movements while the head is stationary and will be performed by the control group. These eye movements will be performed against a plain background in order to eliminate retinal slip and, therefore, eliminate the error signal for vestibular adaptation.